Lanadelumab: A Review in Hereditary Angioedema

Syed, Yahiya Y.

doi:10.1007/s40265-019-01206-w

Cited by 10 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HAE can be treated with purified C1 inhibitor, with the B2R antagonist icatibant or with kallikrein inhibitors such as the small molecule ecallantide 86 , the monoclonal antibody ranadelumab 87 or the oral inhibitor berotralstat 88 .…”

Section: Interactions In Inflammationmentioning

confidence: 99%

Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

et al. 2021

View full text Add to dashboard Cite

Section: Interactions In Inflammationmentioning

confidence: 99%

Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

et al. 2021

View full text Add to dashboard Cite

“…Historically, the patient has never responded to agents targeted to the allergic cascade but has responded well to those targeting elements of the contact-kinin system, which are FDA-approved to treat HAE but not AAE [8,9]. Despite this, multiple cases of AAE have been successfully treated with lanadelumab [10][11][12].…”

Section: Discussionmentioning

confidence: 99%

Acquired Non-histaminergic Angioedema With C1q Autoantibody and Urticaria: A Case Report

Kochvar,

Cobb,

Bernabe

et al. 2023

Cureus

View full text Add to dashboard Cite

Acquired angioedema (AAE) is a rare disease with life-threatening complications. This pathology has classically been associated with medication use and B cell lymphoproliferative disorders. In this report, we describe a 61-year-old man with a six-year history of angioedema, unrelated to any known triggers or malignancy. Extensive workup has led to a diagnosis of idiopathic nonhistaminergic AAE with normal C1 inhibitor. The patient is currently being treated with lanadelumab, which has resolved the patient’s symptoms. This case provides insight into the onset, exploration, treatment, and outcomes of an extremely rare disease process.

show abstract

“…Treatment modalities for angioedema are described in Table 3 [3,[5][6][7][8][9][10][11][12][13][14][15].…”

Section: Therapeutic Modalities For Angioedemamentioning

confidence: 99%

Angioedema of Vermilion Border Lip: A Case Report

Mohan¹,

Chinnakutti²,

Murugesan³

et al. 2022

Cureus

View full text Add to dashboard Cite

Angioedema is the diffuse edematous swelling of the soft tissues that most commonly involves the submucosal and subcutaneous connective tissues. It can also affect the connective tissues of the respiratory and gastrointestinal tract. The most common pathogenesis is the degranulation of mast cells, leading to histamine release and increased vascular permeability. The immunoglobulin E (IgE)-mediated hypersensitivity reactions are triggered by foods, preservatives such as sodium benzoate used in peanut butter, dust, drugs like angiotensin-converting enzyme inhibitors (ACE) like captopril, enalapril, lisinopril and pollens, and contact allergies started by prolonged contact with dental rubber dams and cosmetics. Hereditary factors such as quantitative reduction of C1 esterase inhibitor (C1-INH) deficiency and dysfunctional C1 esterase inhibitor (C1-INH) are also postulated in its etiopathogenesis. In addition, lymphoproliferative disorders, bacterial or viral infections, lupus erythematosus, and minor trauma from dental procedures may precipitate an angioedema attack.

show abstract

Lanadelumab: A Review in Hereditary Angioedema

Cited by 10 publications

References 23 publications

Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation

Acquired Non-histaminergic Angioedema With C1q Autoantibody and Urticaria: A Case Report

Angioedema of Vermilion Border Lip: A Case Report

Contact Info

Product

Resources

About